Company: PTPI
Filing Date: 2025-02-10
Form Type: S-1/A
Source: 0001410578-25-000108
Chunk: 272

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-10
Form: S-1/A
Chunk 272
---
 with the CRO to perform these studies. As of September 30, 2024, these projects are approximately 91% complete. The Company expects the CRO to complete these studies during the fourth quarter of 2024.

15) Segment Information

The Company manages its operations through segments. The Company’s two segments, Prescription Medications and Medical Devices, focus on the treatment of ED. The Prescription Medications segment consists primarily of operations related to Stendra®, which is sold generally in the United States. The Medical Devices segment consists primarily of operations related to vacuum erection devices, which are sold domestically and internationally. The Company separately presents the costs associated with certain corporate functions as Corporate, primarily consisting of unallocated operating expenses including costs that were not specific to a particular segment but are general to the group, expenses incurred for administrative and accounting staff, general liability and other insurance, professional fees and other similar corporate expenses. Interest and other income (expense), net is also not allocated to the operating segments.

The Company’s results of operations by reportable segment for the nine months ended September 30, 2024, are summarized as follows:

| ​                                            
 ​                                            
 For the Nine Months Ended September 30, 2024 | ​ | ​            
 Prescription 
 Medications  |          ​ | ​ | ​       
 Medical 
 Devices |         ​ | ​ | ​         
 ​         
 Corporate |          ​ 
          ​ | ​ | ​            
 ​            
 Consolidated |          ​ 
          ​ |
|:---------------------------------------------|:--|:-------------|-----------:|:--|:--------|----------:|:--|:----------|-----------:|:--|:-------------|-----------:|
| Net sales                                    | ​ | $            |  2,086,180 | ​ | $       | 2,300,460 | ​ | $         |          — | ​ | $            |  4,386,640 |
| Cost of goods sold                           | ​ |              |    194,035 | ​ | ​       |   753,911 | ​ | ​         |          — | ​ | ​            |    947,946 |
| Selling, general and administrative expenses | ​ |              |  1,774,594 | ​ | ​       | 1,673,122 | ​ | ​         |  3,851,675 | ​ | ​            |  7,299,391 |
| Research and development expenses            | ​ |              |  2,